Increasing medication access to transplant recipients

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Transplant recipients require numerous medications to maintain graft survival and health. Post-transplant medication therapy costs greater than $12 000 annually, and the cost of therapy is expected to increase. Although medication costs continue to rise, a substantial portion of Americans lack adequate health insurance or do not have any insurance coverage. To facilitate health, it is imperative that health care providers are familiar with programs that are available to increase prescribed medication access to transplant recipients. The purpose of this manuscript is to provide an overview of common programs available to increase transplant recipients' access to medications. In addition to discussing the consequences of medication non-compliance, this manuscript reviews Medicare, Medigap, Medicaid, Qualified Medicare Beneficiaries, and pharmaceutical manufacturers' medication assistance programs and its use to increase medication access to solid-organ transplant recipients.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalClinical Transplantation
Volume18
Issue number1
DOIs
StatePublished - Feb 1 2004

Fingerprint

Medicare
Costs and Cost Analysis
Transplants
Insurance Coverage
Medication Adherence
Medicaid
Health
Graft Survival
Health Insurance
Health Personnel
Transplant Recipients
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Increasing medication access to transplant recipients. / Chisholm-Burns, Marie.

In: Clinical Transplantation, Vol. 18, No. 1, 01.02.2004, p. 39-48.

Research output: Contribution to journalReview article

@article{6b05472c67f64427ba9cc822f91aa8a7,
title = "Increasing medication access to transplant recipients",
abstract = "Transplant recipients require numerous medications to maintain graft survival and health. Post-transplant medication therapy costs greater than $12 000 annually, and the cost of therapy is expected to increase. Although medication costs continue to rise, a substantial portion of Americans lack adequate health insurance or do not have any insurance coverage. To facilitate health, it is imperative that health care providers are familiar with programs that are available to increase prescribed medication access to transplant recipients. The purpose of this manuscript is to provide an overview of common programs available to increase transplant recipients' access to medications. In addition to discussing the consequences of medication non-compliance, this manuscript reviews Medicare, Medigap, Medicaid, Qualified Medicare Beneficiaries, and pharmaceutical manufacturers' medication assistance programs and its use to increase medication access to solid-organ transplant recipients.",
author = "Marie Chisholm-Burns",
year = "2004",
month = "2",
day = "1",
doi = "10.1111/j.1399-0012.2004.00114.x",
language = "English (US)",
volume = "18",
pages = "39--48",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Increasing medication access to transplant recipients

AU - Chisholm-Burns, Marie

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Transplant recipients require numerous medications to maintain graft survival and health. Post-transplant medication therapy costs greater than $12 000 annually, and the cost of therapy is expected to increase. Although medication costs continue to rise, a substantial portion of Americans lack adequate health insurance or do not have any insurance coverage. To facilitate health, it is imperative that health care providers are familiar with programs that are available to increase prescribed medication access to transplant recipients. The purpose of this manuscript is to provide an overview of common programs available to increase transplant recipients' access to medications. In addition to discussing the consequences of medication non-compliance, this manuscript reviews Medicare, Medigap, Medicaid, Qualified Medicare Beneficiaries, and pharmaceutical manufacturers' medication assistance programs and its use to increase medication access to solid-organ transplant recipients.

AB - Transplant recipients require numerous medications to maintain graft survival and health. Post-transplant medication therapy costs greater than $12 000 annually, and the cost of therapy is expected to increase. Although medication costs continue to rise, a substantial portion of Americans lack adequate health insurance or do not have any insurance coverage. To facilitate health, it is imperative that health care providers are familiar with programs that are available to increase prescribed medication access to transplant recipients. The purpose of this manuscript is to provide an overview of common programs available to increase transplant recipients' access to medications. In addition to discussing the consequences of medication non-compliance, this manuscript reviews Medicare, Medigap, Medicaid, Qualified Medicare Beneficiaries, and pharmaceutical manufacturers' medication assistance programs and its use to increase medication access to solid-organ transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=1042280979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042280979&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2004.00114.x

DO - 10.1111/j.1399-0012.2004.00114.x

M3 - Review article

VL - 18

SP - 39

EP - 48

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1

ER -